Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

Novartis drops two drug candidates, takes $600 million hit

October 6, 2010
Research and Development Human Genome Sciences, Novartis, candidiasis, hepatitis

Novartis will incur a charge of nearly $600 million after it halted development of investigational drugs for hepatitis C and …

News

Novartis sells bladder treatment rights to Warner Chilcott

September 24, 2010
Sales and Marketing Enablex, Novartis, Warner Chilcott

Novartis is to sell the US rights to market its overactive bladder treatment Enablex to Warner Chilcott. Novartis will receive …

News

Gilenya approved as new frontline MS treatment

September 22, 2010
Research and Development, Sales and Marketing Cladribine, FDA, Novartis, gilenya

Novartis’ new multiple sclerosis treatment Gilenya has been approved by the FDA, and is set to significantly alter the way …

News

Novartis hails longer-lasting COPD drug

September 20, 2010
Research and Development, Sales and Marketing COPD, Novartis, Onbrez Breezhaler

A phase III treatment for COPD has demonstrated superior results over GSK’s established Serevent (salmeterol). Data from Novartis’ INSIST study …

News

Swiss approval for Novartis’ Tasigna

August 31, 2010
Sales and Marketing Novartis, Tasigna, Tekamlo

Novartis’ Tasigna has received its first European approval as a first-line treatment after Swiss authorities green-lighted the blood cancer drug …

News

Alcon acquisition makes Novartis eyecare leader

August 26, 2010
Sales and Marketing Novartis, ophthalmology

Novartis has finalised its takeover of Alcon that will make it the world’s number one company in ophthalmology. Alcon is …

News
PakistanFloodWEB

Pharma provides aid for Pakistan

August 24, 2010
Sales and Marketing GSK, NGO, Novartis, Pakistan, disaster, pharma, relief

 The pharma industry is providing donations to help those affected by the mass flooding across Pakistan. As many as 20 …

News

Novartis and Quark sign gene silencing deal

August 19, 2010
Research and Development Novartis, Quark, SiRNA, rnai

Novartis has joined the race to develop a ‘gene silencing’ treatment by signing a new deal with siRNA specialist Quark …

News

NICE decides Xolair is not value for money

August 12, 2010
Sales and Marketing NICE, Novartis, Xolair

NICE has refused to back the use of Novartis’ Xolair for young children, saying the asthma drug’s cost brings little …

News

Two $1 billion dollar acquisition deals go through

August 11, 2010
Sales and Marketing Alcon, M&A, MA, Novartis, Ratiopharm, Teva

Two major acquisition deals mounted by Teva and Novartis are in their final stages as they move to complete potentially …

News
Novartis Tasigna website

Digital Pharma: Novartis rapped for Facebook sharing

August 10, 2010
Medical Communications Digital Pharma blog, Facebook, Novartis, Tasigna

Novartis has had its knuckles rapped by the FDA over the company’s use of social media sharing tools. At issue …

News
Blog footer

Digital Pharma: Novartis game takes aim at ticks

July 30, 2010
Medical Communications Digital Pharma blog, Novartis, digital patients, disease awareness campaigns, encephalitis

Novartis has launched a new online game to raise awareness of the risks posed by ticks and how to avoid …

News

New products spur Novartis growth

July 15, 2010
Sales and Marketing Novartis, Tasigna

Novartis has posted strong results for the second quarter of the year. The Swiss pharma company posted an 11% rise …

News

NICE poised to reject Novartis’ Afinitor

July 8, 2010
Sales and Marketing Afinitor, NICE, Novartis

Novartis’ kidney cancer drug Afinitor does not offer enough benefit to patients to justify its cost, according to draft guidance …

News

NICE rejects Glivec as adjuvant therapy

June 24, 2010
Sales and Marketing Glivec, NICE, Novartis

NICE has rejected the use of Novartis’ Glivec as an adjuvant treatment for people who have had a gastrointestinal stromal …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025